Abbott wins FDA approval for dual-energy ablation catheter

CEO Robert Ford has said the atrial fibrillation treatment, along with the company’s Volt PFA device, is expected to help Abbott regain market share in electrophysiology.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top